Treatment with a drug used to prevent organ rejection partially reverses the course of tuberous sclerosis, research in mice suggests.
Drugs that target “epigenetic” changes may help treat or slow the progression of lung cancer.
Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug.